Oruka Therapeutics (ORKA) Stock Analysis

What Oruka Therapeutics does

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Key metrics

ETFs linked to ORKA

Broad-market and Healthcare sector ETFs an investor holding Oruka Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ORKA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Oruka Therapeutics?

Oruka Therapeutics trades under the ticker ORKA on NASDAQ.

Which exchange is ORKA listed on?

ORKA is listed on NASDAQ.

What sector does Oruka Therapeutics operate in?

Oruka Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ORKA in a portfolio?

PortView shows ORKA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.